2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC boosted its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 1.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,176,244 shares of the company’s stock after acquiring an additional 13,144 shares during the quarter. Geode Capital Management LLC’s holdings in 2seventy bio were worth $5,553,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Erste Asset Management GmbH acquired a new position in 2seventy bio in the third quarter worth approximately $25,000. SkyView Investment Advisors LLC increased its position in 2seventy bio by 25.0% during the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares during the last quarter. Readystate Asset Management LP bought a new position in shares of 2seventy bio in the third quarter valued at approximately $53,000. GSA Capital Partners LLP bought a new position in shares of 2seventy bio in the third quarter worth about $64,000. Finally, Intech Investment Management LLC bought a new position in 2seventy bio during the third quarter worth $69,000. 93.90% of the stock is currently owned by institutional investors.

2seventy bio Stock Performance

NASDAQ TSVT opened at $2.91 on Friday. 2seventy bio, Inc. has a twelve month low of $2.78 and a twelve month high of $6.40. The stock has a market cap of $150.12 million, a PE ratio of -1.56 and a beta of 1.69. The firm has a 50-day simple moving average of $3.70 and a 200 day simple moving average of $4.24.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.